Datum Källa Rubrik Typ Alternativ
2023-07-24 Ziccum Ziccum säkrar andra Feasibility-avtalet på två månader: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Ziccum Ziccums Q2-rapport - VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Ziccum ZICCUM AB (publ) Interim report Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-17 Ziccum Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Ziccum Ziccum sponsors the Global mRNA-Based Therapeutics Summit, Boston MA, July 26-28 Pressreleaser Ladda ner | Visa Stäng
2023-06-05 Ziccum Ziccum joint proposal not selected for detailed application in current CEPI Call Pressreleaser Ladda ner | Visa Stäng
2023-06-02 Ziccum Ziccum appoints senior biopharma executive as new CFO Pressreleaser Ladda ner | Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit med Ziccum Pressreleaser Visa Stäng
2023-05-30 Ziccum Ziccum AB: BioStock Life Science Spring Summit with Ziccum Pressreleaser Visa Stäng
2023-05-26 Ziccum Aerosol and inhalation authority Per Gerde joins Board of Directors of Ziccum AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Ziccum Ziccum CEO to present at BioStock Life Science Spring Summit Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Kommuniké från årsstämma i Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Ziccum Bulletin from the Annual General Meeting of Ziccum AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Ziccum Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies Pressreleaser Ladda ner | Visa Stäng
2023-05-09 Ziccum Ziccums Q1-resultat: VD-uppdatering på svenska Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Ziccum KOMPLETTERING TILL KALLELSEN TILL ÅRSSTÄMMA I ZICCUM AB (PUBL), ATT HÅLLAS DEN 24 MAJ 2023, KL. 11.00 I BOLAGETS LOKALER PÅ SCHEELEVÄGEN 22 I LUND Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Ziccum Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection Pressreleaser Ladda ner | Visa Stäng
2023-04-26 Ziccum ZICCUM AB (publ) releases Interim report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-24 Ziccum KALLELSE TILL ÅRSSTÄMMA I ZICCUM AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Ziccum Ziccum reports positive results from drying of active mRNA and promising mRNA activity after powder reconstitution Pressreleaser Ladda ner | Visa Stäng
2023-03-17 Ziccum Ziccum to attend BIO-Europe Spring in Basel Pressreleaser Ladda ner | Visa Stäng
2023-03-10 Ziccum Ziccum AB joins innovative financial platform for Investor Relations management and European outreach Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Ziccum ZICCUM AB (publ) releases Annual Report 2022 Rapporter Ladda ner | Visa Stäng
2023-01-27 Ziccum ZICCUM AB (publ) Year-end report Q4 2022 Analyser Ladda ner | Visa Stäng
2023-01-23 Ziccum Ziccum submits Expression of Interest for CEPI funding Analyser Ladda ner | Visa Stäng
2023-01-18 Ziccum Ziccum CEO to present at international mRNA Summit in Berlin Analyser Ladda ner | Visa Stäng
2022-12-16 Ziccum Ziccum awarded 10 MSEK Eurostars funding for 3D-modeling and Digital twin project Analyser Ladda ner | Visa Stäng
2022-12-14 Ziccum Ziccum launches new, expanded website Analyser Ladda ner | Visa Stäng
2022-12-08 Ziccum Ziccum signs agreement with Zurich University of Applied Sciences on advanced 3D-modeling project Analyser Ladda ner | Visa Stäng
2022-10-28 Ziccum Ziccums Q3-resultat: VD-uppdatering på svenska Analyser Ladda ner | Visa Stäng
2022-10-27 Ziccum ZICCUM AB (publ) Interim report Q3 2022 Analyser Ladda ner | Visa Stäng
2022-10-24 Ziccum Ziccum generates proof of successful drying of lipid nanoparticles in mRNA project Analyser Ladda ner | Visa Stäng
2022-09-27 Ziccum Ziccum reopens application for CEPI funding on thermostable vaccines with new partner Analyser Ladda ner | Visa Stäng
2022-09-23 Ziccum Ziccum receives results from evaluation study with leading Pharmaceutical Corporation Analyser Ladda ner | Visa Stäng
2022-09-14 Ziccum Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding Analyser Ladda ner | Visa Stäng
Analyser | 14 Sep 2022 | Ziccum

Ziccum and Zurich University of Applied Sciences submit joint application for Eurostars funding

Following their agreed collaboration, Ziccum AB and the team from the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW) have now submitted an application to the Eurostars funding body. The proposed project will develop 3D modelling, and ultimately a Digital Twin, of LaminarPace (LAPA) that will accelerate development and scale-up and promote tech transfer, partnering and ultimately sales.

The team from ZHAW, headed by Prof. Dr. Gernot Boiger, has collaborated with the Ziccum team at Lund to produce a detailed application for their joint project, which has already generated valuable data on LAPA – Ziccum’s unique unique ambient drying system that can dry vaccines and biologics at room temperature, producing robust dry formulations that require no refrigeration or freezing. In the first phase of the proposed project the teams plan to work on 3D modelling of LAPA’s flow, particle formulation and scale-out. A projected final phase aims to further develop the 3D modeling.

Prof. Dr. Gernot Boiger, Head of Research Area Multiphysics Modelling and Imaging at the School of Engineering, ZHAW: “In this collaborative effort we haven’t just learned to work together seamlessly, we have also managed to compose a strong Eurostars proposal. This proposal will be the foundation for carrying out innovative R&D together over the coming years. I think that bringing the teams of Ziccum and ZHAW/ICP together has really worked well.”

Ziccum CEO Ann Gidner: “We’re already hard at work with our great partners at ZHAW,who share our drive and commitment to this unique and much-needed drying technology. We believe this project will significantly strengthen and accelerate the development of LAPA, delivering insights into the unique properties of the particles LAPA can formulate, and accelerating its industrialization.”

About LAPA: LAPA is Ziccum’s unique ambient drying system for vaccines and biologics. In the field of vaccines, LAPA formulates thermostable vaccines that can withstand elevated temperatures without requiring refrigeration or freezing. In the field of biologic drugs, LAPA meets the unmet need for an ambient drying method, drying delicate proteins and viruses at room temperature without the damaging effects of heat. This gives particles that typically retain robust structures and high API activity, making them thermostable – and highly valuable for novel formulation techniques.

About Eurostars: Eurostars funds innovative collaborative R&D projects across 37 member countries, specializing in projects that partner SMEs with larger companies, universities and research organizations. Eurostars is co-funded by the EU Horizon 2020 Framework Programme and EUREKA, the world’s largest public network for international cooperation in R&D and innovation.

For more information about Ziccum, please contact:

2022-09-01 Ziccum Ziccum on the move: company to attend major industry events across Europe in 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Ziccum ZICCUM AB (publ) Interim report Q2 2022 Analyser Ladda ner | Visa Stäng

Kommande händelser

17 May 2024 | Årligutdelning
28 May 2024 | Årsstämma 2023
30 Jul 2024 | Kvartalsrapport 2024-Q2
29 Oct 2024 | Kvartalsrapport 2024-Q3
29 Jan 2025 | Bokslutskommuniké 2024